Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: An AIDS clinical trials group study

Journal of Infectious Diseases

Volumn 202, Issue 5, 2010, Pages 717-722

  Ribaudo, Heather J ^a,b   Liu, Huan ^a,b   Schwab, Matthias ^j,k   Schaeffeler, Elke ^j   Eichelbaum, Michel ^j   Motsinger Reif, Alison A ^d   Ritchie, Marylyn D ^e   Zanger, Ulrich M ^j   Acosta, Edward P ^f   Morse, Gene D ^g   Gulick, Roy M ^h   Robbins, Gregory K ^c   Clifford, David ⁱ   Haas, David W ^e  

^a Statistical Data Analysis Center   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD UNIVERSITY   (United States)

^d NORTH CAROLINA STATE UNIVERSITY   (United States)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g UNIVERSITY AT BUFFALO   (United States)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

ⁱ WASHINGTON UNIVERSITY   (United States)

^j UNIVERSITY OF TÜBINGEN   (Germany)

^k UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ;

ABCB1 GENE; ARTICLE; CYP2B6 GENE; CYP3A5 GENE; DRUG METABOLISM; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RACE DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

AFRICAN CONTINENTAL ANCESTRY GROUP; ANTI-HIV AGENTS; ARYL HYDROCARBON HYDROXYLASES; BENZOXAZINES; CYTOCHROME P-450 CYP3A; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HIV INFECTIONS; HUMANS; MALE; OXIDOREDUCTASES, N-DEMETHYLATING; P-GLYCOPROTEIN; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 77955685573     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/655470     Document Type: Article

References (15)

1. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA 2006; 296:769-781.
2. Clifford DB, Evans S, Yang Y, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med 2005; 143:714-721.
3. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004; 18:2391-2400.
4. Haas DW, Smeaton LM, Shafer RW, et al. Pharmacogenetics of longterm responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an Adult AIDS Clinical Trials Group study. J Infect Dis 2005; 192:1931-1942.
5. Wang J, Sonnerborg A, Rane A, et al. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genomics 2006; 16:191-198.
6. Wyen C, Hendra H, Vogel M, et al. Impact of CYP2B6 983T1C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother 2008; 61:914-918.
7. Rotger M, Tegude H, Colombo S, et al. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIVinfected individuals. Clin Pharmacol Ther 2007; 81:557-566.
8. Rotger M, Saumoy M, Zhang K, et al. Partial deletion of CYP2B6 owing to unequal crossover with CYP2B7. Pharmacogenet Genomics 2007; 17: 885-890.
9. Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002; 359:30-36.
10. Robbins GK, De GV, Shafer RW, et al. Comparison of sequential threedrug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349:2293-2303.
11. Blievernicht JK, Schaeffeler E, Klein K, Eichelbaum M, Schwab M, Zanger UM. MALDI-TOF mass spectrometry for multiplex genotyping of CYP2B6 single-nucleotide polymorphisms. Clin Chem 2007; 53: 24-33.
12. Acosta EP, King JR. Methods for integration of pharmacokinetic and phenotypic information in the treatment of infection with human immunodeficiency virus. Clin Infect Dis 2003; 36:373-377.
13. De Bakker P, Pereyra F, Jia X, et al. A genome-wide association study in HIV-1 controllers. In: Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections. 2009. Abstract 541.
14. Haas DW, Gebretsadik T, Mayo G, et al. Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African Americans. J Infect Dis 2009; 199:872-880.
15. Gatanaga H, Hayashida T, Tsuchiya K, et al. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin Infect Dis 2007; 45:1230-1237.